| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-22542-50ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-49891-0.1mg | |||
| BSA Free | NBP2-49891-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64761-100ug | |||
| BSA Free | NB100-64761-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65338-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43433-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-61727-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-61681-0.025ml | |||
![Western Blot: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of 25 ug of Raji (Lane 1), Jurkat (Lane 2), and BAF-3 cell lysates (Lane 3) and a molecular weight protein ladder.](http://images.novusbio.com/fullsize/CD58-LFA-3-Antibody-TS2-9-Western-Blot-NBP2-22542-img0005.jpg "Western Blot: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of 25 ug of Raji (Lane 1), Jurkat (Lane 2), and BAF-3 cell lysates (Lane 3) and a molecular weight protein ladder.")
![Immunocytochemistry/Immunofluorescence: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of CD58 (green) showing staining in the cytoplasm of Raji cells (right) compared to a negative control without primary antibody (left).](http://images.novusbio.com/fullsize/CD58-LFA-3-Antibody-TS2-9-Immunocytochemistry-Immunofluorescence-NBP2-22542-img0004.jpg)
![Flow Cytometry: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of CD58 in BAF-3 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/CD58-LFA-3-Antibody-TS2-9-Flow-Cytometry-NBP2-22542-img0003.jpg)
![Flow Cytometry: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of CD58 in PBMC cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/CD58-LFA-3-Antibody-TS2-9-Flow-Cytometry-NBP2-22542-img0001.jpg)
![Flow Cytometry: CD58/LFA-3 Antibody (TS2/9) [NBP2-22542] - Analysis of CD58 in PBMC cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/CD58-LFA-3-Antibody-TS2-9-Flow-Cytometry-NBP2-22542-img0002.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a DyLight 649 and Mouse IgG1 FITC isotype control. Figure B. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a PE and Mouse anti Canine CD3 FITC.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0009.jpg "Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a DyLight 649 and Mouse IgG1 FITC isotype control. Figure B. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a PE and Mouse anti Canine CD3 FITC.")
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A: APC conjugated rat anti-Canine CD4 and FITC conjugated mouse IgG1 isotype control. Figure B: APC conjugated rat anti-Canine CD4 and FITC conjugated mouse anti-Canine CD3.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0001.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A: RPE conjugated Rat anti-Dog CD4 and Mouse IgG1 isotype control labeled with Goat anti-Mouse FITC. Figure B: RPE conjugated Rat anti-Dog CD4 and Mouse anti-Dog CD3 labeled with Goat anti Mouse DyLight FITC.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0002.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. Alexa Fluor 700 conjugated Rat anti Canine CD8 and FITC conjugated Mouse IgG1 isotype control. Figure B. Alexa Fluor 700 conjugated Rat anti Canine CD8 and FITC conjugated Mouse anti Canine CD3.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0003.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. FITC conjugated Mouse anti Canine CD3 and RPE conjugated Rat IgG2a isotype control. Figure B. FITC conjugated Mouse anti Canine CD3 and RPE conjugated Rat anti Canine CD4.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0004.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. RPE conjugated Rat anti Canine CD4 and FITC conjugated Mouse IgG1 isotype control. Figure B. RPE conjugated Rat anti Canine CD4 and FITC conjugated Mouse anti Canine CD3.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0005.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. RPE conjugated Rat anti Canine CD8 and FITC conjugated Mouse IgG1 isotype control. Figure B. RPE conjugated Rat anti Canine CD8 and FITC conjugated Mouse anti Canine CD3.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0006.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. FITC conjugated Mouse anti Canine CD3 and RPE conjugated Rat IgG1 isotype control. Figure B. FITC conjugated Mouse anti Canine CD3 and RPE conjugated Rat anti Canine CD8.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0007.jpg)
![Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. FITC conjugated Mouse anti Canine CD3 and purified Rat IgG2a isotype control detected with Goat anti Rat IgG2a DyLight 649. Figure B. FITC conjugated Mouse anti Canine CD3 and purified Mouse anti Canine CD90 detected with Goat anti Rat IgG2a DyLight 649.](http://images.novusbio.com/fullsize/CD3-Antibody-CA17-2A12-Flow-Cytometry-NBP2-49891-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD25/IL-2 R alpha Antibody (OX-39) [NB100-64761] - Rat lymph node cryosection with Mouse anti Rat CD25 antibody , red in A and Mouse anti Rat CD8, green in B. C is the merged image with nuclei counterstained blue using DAPI. Low power](http://images.novusbio.com/fullsize/CD25-IL-2-R-alpha-Antibody-OX-39-Immunocytochemistry-Immunofluorescence-NB100-64761-img0004.jpg "Immunocytochemistry/Immunofluorescence: CD25/IL-2 R alpha Antibody (OX-39) [NB100-64761] - Rat lymph node cryosection with Mouse anti Rat CD25 antibody , red in A and Mouse anti Rat CD8, green in B. C is the merged image with nuclei counterstained blue using DAPI. Low power")
![Immunohistochemistry-Paraffin: CD25/IL-2 R alpha Antibody (OX-39) [NB100-64761] - Rat lymph node cryosection with Mouse anti Rat CD25 followed by horseradish peroxidase conjugated Goat anti Mouse IgG1 as a detection reagent. Medium power](http://images.novusbio.com/fullsize/CD25-IL-2-R-alpha-Antibody-OX-39-Immunohistochemistry-Paraffin-NB100-64761-img0002.jpg)
![Flow Cytometry: CD25/IL-2 R alpha Antibody (OX-39) [NB100-64761] - Staining of Con A activated rat spleen cells with Mouse anti Rat CD25: Biotin](http://images.novusbio.com/fullsize/CD25-IL-2-R-alpha-Antibody-OX-39-Flow-Cytometry-NB100-64761-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: CD25/IL-2 R alpha Antibody (OX-39) [NB100-64761] - Rat lymph node cryosection with Mouse anti Rat CD25 antibody, red in A and Mouse anti Rat CD8, green in B. C is the merged image with nuclei counterstained blue using DAPI. High power](http://images.novusbio.com/fullsize/CD25-IL-2-R-alpha-Antibody-OX-39-Immunocytochemistry-Immunofluorescence-NB100-64761-img0001.jpg)
![Flow Cytometry: Fc gamma RII/CD32 Antibody (AT10) [NB100-65338] - Analysis using the FITC conjugate of NB100-65338. Staining of human peripheral blood granulocytes.](http://images.novusbio.com/fullsize/Fc-gamma-RII-CD32-Antibody-AT10-Flow-Cytometry-NB100-65338-img0005.jpg "Flow Cytometry: Fc gamma RII/CD32 Antibody (AT10) [NB100-65338] - Analysis using the FITC conjugate of NB100-65338. Staining of human peripheral blood granulocytes.")
![Flow Cytometry: Fc gamma RII/CD32 Antibody (AT10) [NB100-65338] - Analysis using the Biotin conjugate of NB100-65338. Staining of human peripheral blood monocytes with mouse anti human CD32: BIOTIN.](http://images.novusbio.com/fullsize/Fc-gamma-RII-CD32-Antibody-AT10-Flow-Cytometry-NB100-65338-img0004.jpg)
![Immunohistochemistry-Paraffin: CD23/Fc epsilon RII Antibody (EBVCS2) [NBP1-43433] - Human colon tissue stained with . IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD23-Fc-epsilon-RII-Antibody-EBVCS2-Immunohistochemistry-Paraffin-NBP1-43433-img0007.jpg "Immunohistochemistry-Paraffin: CD23/Fc epsilon RII Antibody (EBVCS2) [NBP1-43433] - Human colon tissue stained with . IHC-P image submitted by a verified customer review.")
![Flow Cytometry: CD23/Fc epsilon RII Antibody (EBVCS2) [NBP1-43433] - Analysis using the PerCP/Cy5.5 conjugate of NBP1-43433. Staining of normal human peripheral blood cells with Anti-Human CD19 FITC and Anti-Human CD23 PerCP-Cy5.5. Cells in the lymphocyte gate were used for analysis.](http://images.novusbio.com/fullsize/CD23-Fc-epsilon-RII-Antibody-EBVCS2-Flow-Cytometry-NBP1-43433-img0005.jpg)
![Flow Cytometry: CD23/Fc epsilon RII Antibody (EBVCS2) [NBP1-43433] - Staining of normal human peripheral blood cells with 0.5 ug of Mouse IgG1 kappa Isotype Control Purified (open histogram) or 0.25 ug of Anti-Human CD23 Purified (filled histogram) followed by Anti-Mouse IgG FITC. Cells in the lymphocyte gate were used for analysis.](http://images.novusbio.com/fullsize/CD23-Fc-epsilon-RII-Antibody-EBVCS2-Flow-Cytometry-NBP1-43433-img0001.jpg)
![Flow Cytometry: CD23/Fc epsilon RII Antibody (EBVCS2) [NBP1-43433] - Analysis using the PE conjugate of NBP1-43433. Analysis of human peripheral blood leukocytes using CD23 PE conjugate. This can be used at less than or equal to 0.5 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.](http://images.novusbio.com/fullsize/CD23-Fc-epsilon-RII-Antibody-EBVCS2-Flow-Cytometry-NBP1-43433-img0004.jpg)
![Western Blot: PD-L1 Antibody [NB300-903] - Staining of U2OS cell lysate (35 ug protein in RIPA buffer). Antibody at 0.1 ug/mL. Detected by chemiluminescence.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NB300-903-img0002.jpg "Western Blot: PD-L1 Antibody [NB300-903] - Staining of U2OS cell lysate (35 ug protein in RIPA buffer). Antibody at 0.1 ug/mL. Detected by chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NB300-903] - Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing membrane and cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NB300-903-img0004.jpg)
![Flow Cytometry: PD-L1 Antibody [NB300-903] - Flow cytometric analysis of paraformaldehyde fixed Jurkat cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NB300-903-img0005.jpg)
![Western Blot: PD-L1 Antibody [NB300-903] - Staining of Human Heart lysate (35 ug protein in RIPA buffer). Antibody at 0.01 ug/mL. Detected by chemiluminescence.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NB300-903-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NB300-903] - Immunofluorescence analysis of paraformaldehyde fixed AA431 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing cytoplasmic staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NB300-903-img0003.jpg)
![Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Treatment with HBOT or PFD decreased IL-17A expression in the AD lesions. IHC for IL-17A on mouse skin. Scale bar is 100 um. The number of IL-17A-expressing cells was counted in five high-power fields (HPF) chosen at random in each slide by three different pathologists. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0109297) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-TC11-18H10-Immunohistochemistry-Paraffin-NBP1-72027-img0003.jpg "Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Treatment with HBOT or PFD decreased IL-17A expression in the AD lesions. IHC for IL-17A on mouse skin. Scale bar is 100 um. The number of IL-17A-expressing cells was counted in five high-power fields (HPF) chosen at random in each slide by three different pathologists. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0109297) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: IL-17/IL-17A Antibody (TC11-18H10) [NBP1-72027] - Analysis of anti-IL-17 antibody of mouse spleen at concentration 10 ug/ml.](http://images.novusbio.com/fullsize/IL-17-IL-17A-Antibody-TC11-18H10-Immunohistochemistry-Paraffin-NBP1-72027-img0002.jpg)
![Immunocytochemistry/ Immunofluorescence: IL-17/IL-17A Antibody (TC11-18H10) - Azide and BSA Free [NBP1-72027] - TG2-dependent chemokine production in keratinocytes is critical for IL-17-producing CCR6+ gamma δT-cell & neutrophil dermal infiltration.a, b Effect of DMSO- or IMQ-treated WT- or TG2−/−-CM on CCR6+ gamma δT-cell (a) & CD11b+ Ly-6G+ cell (b) migration according to Transwell migration assays. Flow cytometric analysis of the percentage of cells migrating toward the CM in the presence or absence of anti-CXCL1 (a) & anti-CCL20 (b) antibodies (n = 3/group). c, d WT & TG2−/− mouse-derived CCR6+ gamma δT-cell (c) & CD11b+ Ly-6G+ cell (d) migration in response to recombinant mouse CCL20 & CXCL1, respectively. Data represent the mean ± SEM (n = 3/group). *p < 0.05; **p < 0.01. e, f Cells were isolated from the back skin of WT & TG2−/− mice treated with IMQ for four consecutive days & analyzed by flow cytometry. Representative flow cytometric profiles of CCR6+ gamma δTCRlow cells (e) & CD11bhigh Ly-6G+ cells (f). The percentage of cells is shown. Data represent the mean ± SEM (n = 9/group). g Skin sections were immunostained with CCR6 (green)- & IL-17 (red)-specific antibodies. Nuclei were stained with DAPI (blue). Scale bar, 100 μm. h–j Back skin was separated into epidermis & dermis & analyzed by RT-PCR for IL-17-producing gamma δT-cell markers (h) (Ccr6 & Il23r), IL17 & related cytokines (i) (Il17a, Il17f, & Il22), & myeloid cell-derived cytokines (j) (Il12a & Il23a). Data represent the mean ± SEM (n = 11/group). *p < 0.05; **p < 0.01 vs. WT mice. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32355189), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-72027_rat-il-17-il-17a-mab-tc11-18h10-azide-and-bsa-free-310202416171471.jpg)
![Immunocytochemistry/Immunofluorescence: CD2 Antibody (OX-34) [NB100-65228] - (A, B, C) Egg chambers at S6 stained with antibodies against SMRTER and Hindsight (Hnt) (A), CD2 (B), or Cut (C). (D) An egg chamber at S4 stained with antibodies against SMRTER and Cut. (E, F) Egg chambers at S8/S9 stained with antibodies against SMRTER and CD2 (E) or Hnt (F). (G) An egg chamber at S10A stained with antibodies against SMRTER and Hnt.](http://images.novusbio.com/fullsize/CD2-Antibody-OX-34-Immunofluorescence-NB100-65228-img0004.jpg "Immunocytochemistry/Immunofluorescence: CD2 Antibody (OX-34) [NB100-65228] - (A, B, C) Egg chambers at S6 stained with antibodies against SMRTER and Hindsight (Hnt) (A), CD2 (B), or Cut (C). (D) An egg chamber at S4 stained with antibodies against SMRTER and Cut. (E, F) Egg chambers at S8/S9 stained with antibodies against SMRTER and CD2 (E) or Hnt (F). (G) An egg chamber at S10A stained with antibodies against SMRTER and Hnt.")
![Flow Cytometry: CD2 Antibody (OX-34) [NB100-65228] - Figure A. RPE conjugated Mouse anti Rat CD2 and FITC conjugated Mouse IgM isotype control. Figure B. RPE conjugated Mouse anti Rat CD2 and FITC conjugated Mouse anti Rat CD3.](http://images.novusbio.com/fullsize/CD2-Antibody-OX-34-Flow-Cytometry-NB100-65228-img0003.jpg)
![Flow Cytometry: CD2 Antibody (OX-34) [NB100-65228] - Figure A. FITC conjugated Mouse anti Rat CD3 and RPE conjugated Mouse IgG2a isotype control. Figure B. FITC conjugated Mouse anti Rat CD3 and RPE conjugated Mouse anti Rat CD2.](http://images.novusbio.com/fullsize/CD2-Antibody-OX-34-Flow-Cytometry-NB100-65228-img0001.jpg)
![Flow Cytometry: CD2 Antibody (OX-34) [NB100-65228] - Figure A. FITC conjugated Mouse anti Rat CD3 and RPE conjugated Mouse IgG2a isotype control. Figure B. FITC conjugated Mouse anti Rat CD3 and RPE conjugated Mouse anti Rat CD2.](http://images.novusbio.com/fullsize/CD2-Antibody-OX-34-Flow-Cytometry-NB100-65228-img0002.jpg)
![Western Blot: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis using CD2 mAb against HEK293 (1) and CD2 (AA: 25-140)-hIgGFc transfected HEK293 (2) cell lysate.](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Western-Blot-NBP2-61727-img0006.jpg "Western Blot: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis using CD2 mAb against HEK293 (1) and CD2 (AA: 25-140)-hIgGFc transfected HEK293 (2) cell lysate.")
![Immunohistochemistry-Paraffin: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis of endometrial cancer tissues using CD2 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Immunohistochemistry-NBP2-61727-img0004.jpg)
![Flow Cytometry: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis of HepG2 cells using CD2 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Flow-Cytometry-NBP2-61727-img0008.jpg)
![Western Blot: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis using CD2 mAb against human CD2 (AA: 25-140) recombinant protein. Expected MW is 39.2 kDa.](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Western-Blot-NBP2-61727-img0005.jpg)
![Western Blot: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis using CD2 mouse mAb against MOLT4 (1), MCF-7 (2), L1210 (3), U937 (4), and NIH3T3 (5) cell lysate.](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Western-Blot-NBP2-61727-img0007.jpg)
![Immunohistochemistry-Paraffin: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis of rectum cancer tissues using CD2 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Immunohistochemistry-NBP2-61727-img0003.jpg)
![Flow Cytometry: CD2 Antibody (3D1E3) [NBP2-61727] - Analysis of HeLa cells using CD2 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-Flow-Cytometry-NBP2-61727-img0002.jpg)
![ELISA: CD2 Antibody (3D1E3) [NBP2-61727] - Black line: Control Antigen (100 ng); Purple line: Antigen (10 ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng).](http://images.novusbio.com/fullsize/CD2-Antibody-3D1E3-ELISA-NBP2-61727-img0001.jpg)
![Western Blot: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis using CD183 mAb against HEK293 (1) and CD183 (AA: extra mix)-hIgGFc transfected HEK293 (2) cell lysate.](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Western-Blot-NBP2-61681-img0006.jpg "Western Blot: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis using CD183 mAb against HEK293 (1) and CD183 (AA: extra mix)-hIgGFc transfected HEK293 (2) cell lysate.")
![Immunohistochemistry: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis of paraffin-embedded esophageal cancer tissues using CD183 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Immunohistochemistry-NBP2-61681-img0004.jpg)
![Flow Cytometry: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis of Ramos cells using CD183 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Flow-Cytometry-NBP2-61681-img0008.jpg)
![Western Blot: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis using CD183 mAb against human CD183 (AA: extra mix) recombinant protein. (Expected MW is 38.3 kDa)](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Western-Blot-NBP2-61681-img0005.jpg)
![Western Blot: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis using CD183 mouse mAb against Hela (1) and L-02 (2) cell lysate.](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Western-Blot-NBP2-61681-img0007.jpg)
![Immunohistochemistry: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis of paraffin-embedded cervical cancer tissues using CD183 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Immunohistochemistry-NBP2-61681-img0003.jpg)
![Flow Cytometry: CXCR3 Antibody (5C10E6) [NBP2-61681] - Analysis of Jurkat cells using CD183 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-Flow-Cytometry-NBP2-61681-img0002.jpg)
![ELISA: CXCR3 Antibody (5C10E6) [NBP2-61681] - Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)](http://images.novusbio.com/fullsize/CXCR3-Antibody-5C10E6-ELISA-NBP2-61681-img0001.jpg)
![Western Blot: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis using IRAK4 mouse mAb against THP-1 (1), Hela (2), K562 (3), MCF-7 (4), RAW264.7 (5), Jurkat (6) and Cos7 (7) cell lysate.](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-Western-Blot-NBP2-37575-img0003.jpg "Western Blot: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis using IRAK4 mouse mAb against THP-1 (1), Hela (2), K562 (3), MCF-7 (4), RAW264.7 (5), Jurkat (6) and Cos7 (7) cell lysate.")
![Immunohistochemistry-Paraffin: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis of human kidney cancer tissues using IRAK4 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-Immunohistochemistry-NBP2-37575-img0006.jpg)
![Flow Cytometry: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis of Hela cells using IRAK4 mouse mAb (blue) and negative control (red).](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-Flow-Cytometry-NBP2-37575-img0004.jpg)
![Western Blot: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis using IRAK4 mAb against human IRAK4 (AA: 21-198) recombinant protein. (Expected MW is 45.4 kDa)](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-Western-Blot-NBP2-37575-img0002.jpg)
![Immunohistochemistry-Paraffin: IRAK4 Antibody (2H9) [NBP2-37575] - Analysis of human lung cancer tissues using IRAK4 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-Immunohistochemistry-NBP2-37575-img0005.jpg)
![ELISA: IRAK4 Antibody (2H9) [NBP2-37575] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);](http://images.novusbio.com/fullsize/IRAK4-Antibody-2H9-ELISA-NBP2-37575-img0001.jpg)
![Western Blot: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD80 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD80.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Western-Blot-NBP2-70364-img0001.jpg "Western Blot: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CD80 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CD80.")
![Immunocytochemistry/Immunofluorescence: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of COS7 cells transiently transfected by pCMV6-ENTRY CD80.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-70364-img0002.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Human pancreas tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0008.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Adenocarcinoma of Human breast tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0003.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Carcinoma of Human lung tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0004.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Carcinoma of Human prostate tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0005.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Human colon tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0006.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Human liver tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0007.jpg)
![Immunohistochemistry: B7-1/CD80 Antibody (OTI2E5) - Azide and BSA Free [NBP2-70364] - Staining of paraffin-embedded Human prostate tissue using anti-CD80 mouse monoclonal antibody.](http://images.novusbio.com/fullsize/B7-1-CD80-Antibody-OTI2E5-Azide-and-BSA-Free-Immunohistochemistry-NBP2-70364-img0009.jpg)